Heron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Heron Therapeutics, Inc. (NASDAQ:HRTX)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.76 and traded as high as $1.81. Heron Therapeutics shares last traded at $1.78, with a volume of 1,155,217 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HRTX shares. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Wednesday, December 4th.

Heron Therapeutics Price Performance

The stock has a market cap of $270.74 million, a P/E ratio of -9.89 and a beta of 1.60. The company has a fifty day moving average of $1.65 and a 200 day moving average of $1.76.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $32.81 million during the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the company posted ($0.17) EPS. As a group, analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Heron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HRTX. Congress Park Capital LLC boosted its holdings in Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after purchasing an additional 477,417 shares in the last quarter. Clearline Capital LP increased its stake in Heron Therapeutics by 48.9% in the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after acquiring an additional 731,246 shares during the period. New York State Common Retirement Fund increased its stake in Heron Therapeutics by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company’s stock valued at $2,021,000 after acquiring an additional 41,062 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after acquiring an additional 9,418 shares during the period. Finally, Northern Trust Corp grew its stake in Heron Therapeutics by 2.2% during the fourth quarter. Northern Trust Corp now owns 1,011,756 shares of the biotechnology company’s stock worth $1,548,000 after buying an additional 21,769 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.